Holst, Jens J.; Lasalle, James R.
September 2008
Journal of Family Practice;Sep2008 Supplement, Vol. 57, pS4
Academic Journal
The article discusses the understanding about the role of incretin hormones in type 2 diabetes mellitus (T2DM). It explores the T2DM which results from a complex pathophysiologic process including pancreatic alpha and beta cell dysfunction, peripheral insulin resistance and impaired function of the incretin hormones. The incretin hormones are found in the gastrointestinal system and other tissues. These are integral to glucose homeostasis, increasing insulin secretion, reducing glucagon secretion, slowing gastric emptying and enhancing early satiety. It is pointed out that the enhancement of the increting system with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors is effective in reestablishing glucose homeostasis.


Related Articles

  • AN OVERVIEW OF INCRETIN CLINICAL TRIALS. Garber, Alan J.; Spann, Stephen J. // Journal of Family Practice;Sep2008 Supplement, Vol. 57, pS10 

    This article reviews many of the key incretin clinical trials, with a focus on the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors compared with placebo and other glucose-lowering agents used as comparators. These agents have...

  • The role of gut hormones in glucose homeostasis. Drucker, Daniel J. // Journal of Clinical Investigation;Jan2007, Vol. 117 Issue 1, p24 

    The gastrointestinal tract has a crucial role in the control of energy homeostasis through its role in the digestion, absorption, and assimilation of ingested nutrients. Furthermore, signals from the gastrointestinal tract are important regulators of gut motility and satiety, both of which have...

  • WHY AND WHEN TO IMPLEMENT INCRETIN THERAPY. Freeman, Jeffrey S.; Unger, Jeff // Journal of Family Practice;Sep2008 Supplement, Vol. 57, pS19 

    The article discusses the understanding about the implementation of increting therapy for type 2 diabetes mellitus (T2DM). It is stated that the two increting agents including glucagon-like peptide-1 receptor and dipeptidyl peptidase-4 inhibitor are useful in the management of T2DM. The agents...

  • HOW TO IMPLEMENT INCRETIN THERAPY. Cobble, Michael E. // Journal of Family Practice;Sep2008 Supplement, Vol. 57, pS26 

    The article focuses on the factors to consider when implementing the glucose-like peptide-1 (GLP-1)receptor agonists and dipeptidyl peptidase-4 inhibitors as monotherapy of type 2 diabetes mellitus (T2DM). It is stated that the two agents can be used as part of a comprehensive plan for managing...

  • Administration of an acylated GLP-1 and preparation provides added beneficial glucose-lowering and insulinotropic actionsover single incretins in mice with type 2 diabetes and obesity.  // Current Medical Literature: Diabetes;2011, Vol. 28 Issue 4, p144 

    The article presents a study which tested the added glucose-lowering and insulinotropic actions of an acylated glucagon-like peptide-1 (GLP-1) receptor liraglutide and glucose-dependent insulinotropic polypeptide (GIP) in mice with type 2 diabetes and obesity. It says that the GIP-liraglutide...

  • Liraglutide's Good Data: Higher Bar for Byetta LAR?  // Bioworld Week;8/3/2009, Vol. 17 Issue 31, p3 

    The article reports on the impact of the result of the glucagon-like peptide-1 analogue liraglutide performed well in a trial enrolling only African Americans with Type II diabetes on the drug's approval in the U.S. It states that the result will not affect the meaning of the drug's eventual...

  • Liraglutide-A Novel GLP-1 Analogue. Kalra, Sanjay; Kalra, Bharti; Sharma, Amit // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Nov2009, Vol. 3 Issue 3, p200 

    Liraglutide is a novel glucagon-like peptide 1 analogue, which shows promise as a safe, effective therapy for type 2 diabetes. This review discusses the pathophysiology of type 2 diabetes, focusing on the incretin system, and reviews the pharmacology of liraglutide. A concise discussion of...

  • Gut-derived incretin hormones and new therapeutic approaches. Bloomgarden, Zachary T. // Diabetes Care;Oct2004, Vol. 27 Issue 10, p2554 

    Discusses therapeutic approaches for diabetes based on gut-derived incretin hormones. Physiology of glucagon-like peptide 1 (GLP-1) action; Potential effects of GLP-1 in type 2 diabetes; Comparison of GLP-1 with other pharmacological agents in diabetes.

  • A GUT RESPONSE. Kordella, Terri // Diabetes Forecast;Apr2004, Vol. 57 Issue 4, p39 

    Focuses on the significance of gut hormones in developing drugs in treating type 2 diabetes. Uses and significance of gut hormones in the body; Kinds of gut hormones; Causes of Type 2 diabetes; Benefits of the gastric emptying process provided by the gut hormone, glycogen-like peptide-1. ...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics